Candidate hookworm vaccine shows benefits in animal study

A paper published in this week's PLoS Medicine shows that vaccination against a protein secreted by the dog hookworm can protect against blood loss and anaemia caused by the same hookworm in dogs. The researchers, led by Alex Loukas and Peter Hotez, showed that vaccination of dogs with recombinant Ac-APR-1, an enzyme that starts the digestion of hemoglobin in hookworms, induced an immune response and resulted in significantly reduced hookworm burdens and fecal egg counts in vaccinated dogs compared to control dogs after challenge with infective larvae of the hookworm Ancylostoma caninum. Most importantly, vaccinated dogs were protected against blood loss and most did not develop anemia, the major result of hookworm disease.

Hookworms are intestinal parasites of mammals, including humans, dogs, and cats; in humans these infections are a leading cause of intestinal blood loss and iron-deficiency anemia. Hookworm infections occur mostly in tropical and subtropical climates and are estimated to infect about 1 billion people worldwide-- about one-fifth of the world's population. People who have direct contact with soil that contains human feces in areas where hookworm is common are at high risk of infection; because children play in dirt, they are at the highest risk.

These results set the stage for the next stage of vaccine development in humans. Loukas and colleagues suggest that the ideal hookworm vaccine would be a mixture of two recombinant proteins, targeting both the infective larva and the blood-feeding adult stage (as targeted here) of the parasite. Such a vaccine would limit the amount of blood loss caused by feeding worms and maintain normal levels of hemoglobin.


Contact: Paul Ocampo
Public Library of Science

Page: 1

Related biology news :

1. Candidate research sites selected for the National Ecological Observatory Network
2. Designed peptides: Candidates for the treatment of cancer, sexual dysfunction, eating disorders
3. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
4. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
5. Handicapping tuberculosis may be the way to a better vaccine
6. Developing a more effective vaccine for tuberculosis
7. New target for HIV/AIDS drugs and vaccine discovered
8. Genomic analysis uncovers new targets for HIV vaccine
9. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
10. Universal flu vaccine being tested on humans
11. From clinical cancer research: rethinking therapeutic cancer vaccine trials

Post Your Comments:
TAG: Candidate hookworm vaccine shows benefits animal study

(Date:9/30/2015)... Calif. , Sept. 30, 2015  With nearly ... the number of new SCIs estimated to reach 12,500 ... Southern California Resource Services for Independent Living ... ILCs in California opening doors ... range of programs and services, notably assistive technology services ...
(Date:9/29/2015)... SUNNYVALE, Calif. , Sept. 29, 2015 ... technology improves employee productivity while also saving energy ... features such as Low Power Active Mode and embedded ... workplace transformation Fujitsu today shows that ... of new and refreshed models to its enterprise desktop ...
(Date:9/28/2015)... Sept. 28, 2015  The monitoring of vital ... body temperature, is an essential component of patient ... of deterioration in a patient,s condition. However, in ... are typically taken during routine observation rounds only ... patient deteriorates between these observation rounds, the warning ...
Breaking Biology News(10 mins):
(Date:10/8/2015)... ... 08, 2015 , ... Cystic fibrosis (CF) is a genetic ... and results in dysfunction of the lungs and the gastrointestinal (GI) tract. In ... is very difficult to clear, blocks the airways and the glands, and creates ...
(Date:10/7/2015)... ... 07, 2015 , ... Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal ... Mar-a-Lago from 3:50 pm to 4:30 pm. , Dr. Riordan is one of the ... He is the Co-Founder and Chief Science Officer of the Riordan-McKenna Institute ...
(Date:10/7/2015)... 2015  ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV ) ... the development and commercialization of targeted antiviral therapies, today ... 5,000,000 shares of its common stock and warrants to ... stock at a fixed combined price to the public ... will be issued separately.  The warrants will be exercisable ...
(Date:10/7/2015)... Pa. , Oct. 7, 2015   VWR ... independent provider of laboratory products, services and solutions, ... Inc. (PTI), a specialty solvent company that performs ... This acquisition will enhance VWR,s growing laboratory and ... laboratory and biopharmaceutical manufacturing customers. Manuel ...
Breaking Biology Technology:
Cached News: